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Aim. To compare two creatinine-based estimated glomerular filtration rate (eGFR) equations, the chronic kidney disease
epidemiology collaboration (CKD-EPI) and the modification of diet in renal disease (MDRD), for predicting the risk of CKD
progression in type 2 diabetic patients with nephropathy. Methods. A total of 707 type 2 diabetic patients with 24 hr urinary
albumin excretion of more than 30mg/day were retrospectively recruited and traced until doubling of baseline serum creatinine
(SCr) levels was noted. Results. During the follow-up period (median, 2.4 years), the CKD-EPI equation reclassified 10.9% of all
MDRD-estimated subjects: 9.1% to an earlier stage of CKD and 1.8% to a later stage of CKD. Overall, the prevalence of CKD
(eGFR < 60mL/min/1.73m2) was lowered from 54% to 51.6% by applying the CKD-EPI equation. On Cox-regression analysis,
both equations exhibited significant associations with an increased risk for doubling of SCr. However, only the CKD-EPI equation
maintained a significant hazard ratio for doubling of SCr in earlier-stage CKD (eGFR ≥ 45mL/min/1.73m2), when compared to
stage 1 CKD (eGFR ≥ 90mL/min/1.73m2). Conclusion. In regard to CKD progression, these results suggest that the CKD-EPI
equation might more accurately stratify earlier-stage CKD among type 2 diabetic patients with nephropathy than theMDRD study
equation.
1. Introduction
An increasing prevalence of chronic kidney disease (CKD)
is garnering greater concern worldwide [1]. Previous studies
have attributed a growing trend inCKD to a rapid aging of the
general population and expansion of the diabetes epidemic
[1–3]. From 1991 to 2001, the incidence of diabetic nephropa-
thy doubled among patients with newly diagnosed end stage
renal disease (ESRD) [4]. Recently, an outstanding cross-
sectional study including 32,208 patients with type 2 diabetes
(T2D) from 33 countries revealed that the overall prevalence
of micro- and macroalbuminuria was about 39% and 10%,
respectively [5]. Making matters worse, the prevalence of
ESRD caused by diabetes is estimated to increase to 70%
by the year 2015 [4]. T2D is well known as a leading cause
of cardiovascular disease (CVD) and ESRD [6]. It is also
well established that CKD has been shown to be strongly
related to increased risks of CVD-related hospitalization and
mortality, as well as ESRD, even after adjusting cardiovascular
risk factors [1, 7, 8]. Therefore, early identification of patients
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with CKD may hold additional clinical implications other
than just the detection of impending progression to ESRD,
especially in patients with T2D [9, 10].
Diagnosis, classification, and management of CKD are
mainly dependent on overall kidney function assessed by
glomerular filtration rate (GFR). To aid in the above, sev-
eral creatinine-based formulas have been developed for
estimating GFR. Most widely used in clinical practice, the
modification of diet in renal disease (MDRD) study equation
for estimating GFR was developed accounting for serum
creatinine concentration, age, sex, and race [1]. Via subse-
quent studies, the prognostic implications of estimated GFR
(eGFR) based on the MDRD study equation (eGFR MDRD)
were revealed [1, 11, 12]. In accordance with these reports,
eGFR MDRD has been widely known to predict the risk of
ESRD in CKD patients, as well as graft failure after kidney
transplant [13, 14].Moreover, decline in eGFRMDRDhas also
been reported to be predictive of clinical outcomes, such as
CVD events and death, particularly in patients with a CKD
(GFR < 60mL/min/1.73m2) [1, 15, 16]. Although the MDRD
study equation has generally been used for estimating GFR
and evaluating CKD, imprecision and underestimation of
GFR have been reported as major limitations, especially in
those with early stage of CKD (GFR ≥ 60mL/min/1.73m2)
[1, 11, 12]. In addition, in diabetic patients with microal-
buminuria or overt diabetic nephropathy, it was reported
that the MDRD Study equation significantly underestimated
GFR [17]. Recently, the chronic kidney disease epidemiology
collaboration (CKD-EPI) equation was developed utilizing a
large database that pooled data from 10 studies and has been
subsequently validated in 16 additional studies [18]. Based on
the same four variables of the MDRD study equation, age,
sex, race, and serum creatinine concentration, the CKD-EPI
equation has proven to be more accurate than the MDRD
Study equation in estimating GFR, especially in patients with
early stage of CKD. However, there have been few studies to
compare the CKD-EPI and MDRD equations with respect to
the risks of clinical outcomes such as loss of kidney function
or progression to ESRD in patients with T2D. Therefore, we
attempted to investigate whether the CKD-EPI equation was
superior to theMDRD equation in predicting decline in renal
function in Korean type 2 diabetic patients with nephropathy.
2. Materials and Methods
2.1. Patients and Study Design. In this retrospective cohort
study, we extracted data from an electronic medical record
(EMR) database of type 2 diabetic subjects with nephropathy
in whom two or more serum creatinine measurements were
made between July 2000 and September 2012 at Severance
Hospital in Seoul, Korea. Patients with type 2 diabetes were
identified by searching the EMR database for the code ICD-
10. Indicative of diabetic nephropathy, we included diabetic
patients with 24 hr urinary albumin excretion ≥ 30mg/day
on at least one measurement. Baseline data were defined as
data measured at the point in time at which 24 hr urinary
albumin excretion level exceeded 30mg/day for the first
time. Patients were excluded if they had undergone renal
replacement therapy at baseline or if they were younger than
18 years. After the baseline data extraction, patients were
retrospectively followed up to two set endpoints: until May
2013 (time endpoint) or until an event of decline in renal
function or death (clinical outcome endpoint). For subjects
who were lost to follow-up, we included data obtained up to
their final visit.
Primary outcome was evaluated according to decline in
renal function and defined as doubling of baseline serum
creatinine level. Doubling of baseline serum creatinine level
was defined as a twofold increase in serum creatinine level
for at least two consecutive measurements. This study was
approved by the Institutional Review Board of Severance
Hospital.
2.2. Clinical and Laboratory Measurements. Demographic
and clinical findings were reviewed retrospectively for age,
gender, duration of diabetes, and medications. Body mass
index (BMI, kg/m2) was calculated by dividing weight (kg)
by height (m) squared. Urinary albumin excretion amounts
were measured with an automatic analyzer, Hitachi 7180
(Hitachi Instruments Service, Tokyo, Japan), in a 24 hr
urine sample. Plasma glucose level was determined by the
glucose oxidase method. HbA1c was measured by high-
performance liquid chromatography using the Variant II
Turbo Hemoglobin Testing System (Bio-Rad Laborato-
ries, Hercules, CA). Plasma total cholesterol, high-density
lipoprotein (HDL) cholesterol, triglycerides (TG), and crea-
tinine measurements were performed using an autoanalyzer
(Hitachi 7600: Hitachi Instruments Service, Tokyo, Japan).
Low-density lipoprotein (LDL) cholesterol was calculated
using the Friedewald formula.
2.3. Estimation of GFR and Classification of CKD. The esti-
mation of GFRwas calculated using the four-variableMDRD
study equation and the CKD-EPI equation [18, 19]:
eGFR (MDRD) = 186.3 × (creatinine)−1.154
× Age−0.203 × 0.742 (if female) ,
eGFR (CKD-EPI) = 141 ×min(creatinine
𝑘
, 1)
𝛼
×max (creatinine
𝑘
, 1)
−1.209
× 0.993
Age
× 1.018 (if female) .
(1)
In the CKD-EPI equation for estimating GFR, k equals
0.7 for females and 0.9 for males; 𝛼 equals −0.329 for
females and −0.411 for males; min refers to the minimum
value for creatinine/k or 1; and max means the maximum
for creatinine/k or 1. For both equations, eGFR was cal-
culated as mL/min/1.73m2, weight in kg, serum creatinine
in mg/dL, and age in years. CKD stage was classified
into five subgroups according to the NKF-KDOQI crite-
ria for CKD: stage 1, eGFR ≥ 90mL/min/1.73m2; stage
2, eGFR of 60–89mL/min/1.73m2; stage 3, eGFR of 30–
59mL/min/1.73m2; stage 4, eGFR of 15–29mL/min/1.73m2;
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and stage 5, eGFR < 15mL/min/1.73m2or dialysis. Stage
3 CKD was further divided into two subgroups: stage
3a, eGFR 45–59mL/min/1.73m2, and stage 3b, eGFR 30–
44mL/min/1.73m2 [12, 20].
2.4. Statistical Analysis. Data are presented as the means
± standard deviation. CKD was defined as an eGFR <
60mL/min/1.73m2 for both equations for eGFR calculation
[12]. Analysis of the associations between eGFR calculated
by each equation and the risk of clinical outcomes was
performed with Cox regression analysis after adjusting for
potential confounding factors, including age, sex, diabetes
duration, and HbA1c. All statistical analyses were performed
with SAS version 9.2 (SAS Institute, Cary, NC, USA), and P
values <0.05 were considered statistically significant.
3. Results
The baseline characteristics of all 707 subjects are shown in
Table 1. Mean age, HbA1c, and duration of diabetes were 61.9
± 12.2 years, 8.2 ± 4.3 %, and 12.7 ± 8.9 years, respectively.
The mean 24 hr urinary albumin excretion amount was
1094.58 ± 1867.38mg/day, and 47.5% of the patients exhibited
macroalbuminuria. The prevalence of CKD, defined as an
eGFR of less than 60mL/min/1.73m2, was 54% (𝑛 = 382) for
theMDRD study equation and 51.6%, (𝑛 = 365) for the CKD-
PEI equation. Oral antidiabetic drugs and insulin were used
in 69.9% and 26.0% of all patients, respectively. In this study,
68.2% and 37.9% of the subjects had also takenmedication for
hypertension and dyslipidemia, respectively.
The most common CKD stage was stage 2 for both the
MDRD study equation and the CKD-EPI equation (Table 1).
Comparing CKD stage for each equation, 10.9% of MDRD-
estimated patients were reclassified by adopting the CKD-
EPI equation. Most reclassifications of CKD stage were
observed in patients with stage 3a (eGFR MDRD of 45–
59mL/min/1.73m2) (Figure 1). Among these patients (𝑛 =
107), 15.9% (𝑛 = 17) were reclassified to a lower stage of
CKD and 0.9% were reclassified to a higher stage of CKD. Of
the 229 patients with CKD stage 2 by eGFR MDRD, 13.5%
(𝑛 = 31) were downwardly reclassified to CKD stage 1 by
eGFR CKD-EPI, lowering the prevalence of CKD stage 2
from 32.4% to 31.4%. In CKD stage 3b patients with an eGFR
MDRD of 30–44mL/min/1.73m2, upward reclassification to
CKD stage 3a by eGFR CKD-EPI occurred in 10.7% (𝑛 = 13)
of 122 patients. In contrast, 7.3% (𝑛 = 7) of 96 patients with
CKD stage 1 by eGFR MDRD were upwardly reclassified to
CKD stage 2 by eGFR CKD-EPI. Overall, the prevalence of
CKD (defined as an eGFR of less than 60mL/min/1.73m2)
decreased from 54% to 51.6% by applying the CKD-EPI
equation. Additionally, reclassification to an earlier stage of
CKD by applying the CKD-EPI equation was likely to occur
in younger subjects (median age, 55.5 versus 64.2 years, P
< 0.001); patients reclassified to a later stage of CKD by
the CKD-EPI equation were older than those who were not
reclassified (median age, 76.8 versus 64.2 years, P < 0.001).
During a median follow-up of 2.4 years, doubling of
serum creatinine level, development of ESRD, incidence of
Table 1: Demographic and baseline characteristics of the partici-
pants (𝑛 = 707).
Variables All
Male/female 416/291
Age (years) 61.9 ± 12.2
Duration of diabetes (years) 12.7 ± 8.9
Duration of follow-up (months) 35.9 ± 49.6
HbA1c (%) 8.2 ± 4.3
Cr (mg/dL) 1.59 ± 1.24
eGFR CKD-EPI(mL/min/1.73m2) 59.08 ± 30.27
Stages, 𝑛 (%)
Stage 1: ≥90 120 (17.0)
Stage 2: 60–89 222 (31.4)
Stage 3a: 45–59 102 (14.4)
Stage 3b: 30–44 113 (16.0)
Stage 4: 15–29 104 (14.7)
Stage 5: <15 46 (6.5)
eGFR MDRD (mL/min/1.73m2) 58.01 ± 31.77
Stages, 𝑛 (%)
Stage 1: ≥90 96 (13.6)
Stage 2: 60–89 229 (32.4)
Stage 3a: 45–59 107 (15.1)
Stage 3b: 30–44 122 (17.3)
Stage 4: 15–29 111 (15.7)
Stage 5: <15 42 (5.9)
24 hr urinary albumin excretion (mg/day) 1094.58 ± 1867.38
Total cholesterol (mg/dL) 174.1 ± 53.9
Triglycerides (mg/dL) 169.6 ± 140.4
HDL cholesterol (mg/dL) 43.5 ± 15.1
LDL cholesterol (mg/dL) 99.3 ± 42.2
Oral hypoglycemic agents (%) 495 (69.9)
Insulin therapy (%) 184 (26.0)
Antihypertensive agents (%) 483 (68.2)
Lipid-lowering agents (%) 268 (37.9)
Data are shown as means ± SD or number of the case (%).
acute myocardial infarction (AMI), and stroke, as well as
death from any cause, occurred in 27.9 % (𝑛 = 197), 13.4%
(𝑛 = 95), 6.5% (𝑛 = 46), 6.5% (𝑛 = 46), and 10.7% (𝑛 =
76) of the participants, respectively. As shown in Figure 2,
advance of CKD stage for both equations was associated
with an increased risk for doubling of serum creatinine level
in a stage-dependent manner. In Cox regression analyses
(Table 2), CKD stage classified by each equation was asso-
ciated with an increased risk for doubling of baseline serum
creatinine levels. Comparing all CKD stages to stage 1 CKD
estimated by both equations, we assessed Cox proportional
hazard ratios (HRs) for doubling of serum creatinine level.
For theMDRD study equation, the Cox proportional HRs for
doubling of serum creatinine level were 1.54 (95%CI, 0.71–
3.31; P = 0.27) for stage 2 and 1.79 (95%CI, 0.79–4.07; P =
0.17) for stage 3a. In contrast, for the CKD-EPI equation, the
Cox proportional HRs for doubling of serum creatinine level
were 1.90 (95%CI, 0.97–3.73; P = 0.063) for stage 2 and 2.18
(95%CI, 1.04–4.55; P = 0.038) for stage 3a. In the advanced
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Figure 1: Ratio (%) of chronic kidney disease (CKD) stages for
the modification of diet in renal disease (MDRD) study equation
reclassified by the chronic kidney disease epidemiology collabo-
ration (CKD-EPI) equation. Blue bars indicate reclassification to
earlier stage of CKD; yellow bars, no reclassification; red bars,
reclassification to later stage of CKD.
stages of CKD (eGFR < 45mL/min/1.73m2), both equations
showed significant HRs for doubling of serum creatinine
level. Inmodel 1, the association of decreased eGFR estimated
by each equation with the risk of baseline creatinine level
doubling remained statistically significant after adjusting for
age and sex. Additionally adjusting for duration of diabetes
in model 2, duration of diabetes and HbA1c in model 3, and
further adjusting for medication for hypertension in model
4, in both Cox regression models, eGFR CKD-EPI showed
greater HRs for doubling of serum creatinine level than eGFR
MDRD did.
4. Discussion
Considering the burden of CKD on public health worldwide,
accurate estimation of renal function is of paramount impor-
tance in managing subjects with renal insufficiency, as well
as in improving morbidity and mortality [18, 21]. Current
clinical guidelines for CKD recommend reporting serum
creatinine-based eGFR using the MDRD study formula,
which includes data for age, sex, race, and serum creatinine
concentration [12, 22]. Based on data from patients with
CKD, the MDRD study equation is limited by imprecision
and underestimation of GFR in patients of early stage of
CKD (GFR ≥ 60mL/min/1.73m2) [23, 24]. Because of these
challenges, application of the MDRD study equation is
considered less useful to classify patients of CKD stages 1
and 2, to verify hyperfiltration, and to track GFR changes in
the higher range [1]. Furthermore, it is reported that eGFR
assessed by the MDRD study equation overdiagnosed CKD,
especially in younger white women [24, 25]. A recent meta-
analysis, based on various populations, revealed that not
only the classification of CKD but also the risk for mortality
and ESRD were more accurately predicted by the CKD-
EPI equation than the MDRD study equation [26]. These
unmet needs drove the advent of a new equation proposed by
the CKD-EPI. Growing evidence has demonstrated that the
CKD-EPI equation might be more accurate than the MDRD
study equation [18, 27–29]. However, the clinical implications
of eGFR assessed by the CKD-EPI equation compared to
that by the MDRD study equation have not yet been well
elucidated in Korean subjects with type 2 diabetes.
The present study demonstrated the superiority of the
CKD-EPI equation over the MDRD study equation in iden-
tifying Korean type 2 diabetic subjects with nephropathy
who were expected to show deteriorations in renal function.
The present study had two main findings: first, compared
with the results from eGFR MDRD, 9.1% of the type 2
diabetic subjects with nephropathy were reclassified to an
earlier stage of CKD after estimation of GFR by the CKD-EPI
equation.This resulted in a decrease in the prevalence of CKD
stages 2, 3, and 4 from 32.4% to 31.4%, 32.4% to 30.4%, and
15.7% to 14.7%, respectively. With respect to discrepancies in
CKD stage between eGFR CKD-EPI and eGFRMDRD, most
studies have reported similar trends in decreased prevalence
of CKD (eGFR < 60mL/min/1.73m2) estimated by the CKD-
EPI equation in comparison to theMDRD study equation [18,
28]. Regarding precision and accuracy, one previous study
demonstrated that eGFR MDRD was imprecise in patients
with an eGFR ≥ 60mL/min/1.73m2, while eGFR CKD-EPI
showed less bias, improved precision, and greater accuracy
than eGFR MDRD [30]. In accordance with this finding,
introduction of theCKD-EPI equation in theNationalHealth
and Nutrition Examination Survey (NHANES) led to a
decrease in the estimated prevalence of CKD from 13.1%
to 11.5% [18]. Furthermore, in a recently conducted cohort
study for subjects with T2D, the prevalence of CKD (eGFR
< 60mL/min/1.73m2) was 22.0% for eGFR MDRD and
20.2% for eGFR CKD-EPI [31]. Because we targeted type 2
diabetic patients with nephropathy in the present study, the
prevalence rate of CKD was nearly twice as high as that of
the previous study. Nonetheless, similar to the previous study,
we observed a decrease in the prevalence of CKD (eGFR <
60mL/min/1.73m2) from 54.0% to 51.6% when estimated by
the CKD-EPI equation. Accordingly, we deduced that the
CKD-EPI equation might allow for better risk assessment
and more effective use of health care resources allocated to
managing CKD-related outcomes, owing to a lower andmore
accurately assessed CKD prevalence [32]. Second, only the
CKD-EPI equation, not the MDRD study equation, was able
to predict the progression of renal insufficiency in type 2
diabetic subjects who already had albuminuria and earlier
stage of CKD (GFR ≥ 45mL/min/1.73m2). As the prevalence
of earlier-stage CKD (10.8%) is more than 100 times greater
than the prevalence of renal failure (0.1%), more accurate
detection of CKD at earlier stages could help not only in
clinical decision making but also in the allocation of public
health care resources, as stated above [9]. In this regard,
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Figure 2: Cox-regression survival curve for doubling of serum creatinine level according to CKD stage for each eGFR equation: MDRD (a)
and CKD-EPI (b). Age and sex are adjusted.
improvement in the early prediction of decline in renal
function before it develops to ESRD might have significant
clinical implications.
Recently, several studies in general population cohorts
have demonstrated that reclassification of eGFR by the CKD-
EPI equation facilitates more accurate prediction of clinical
outcomes than assessment of eGFR by the MDRD study
equation, in particular by shifting lower risk participants to
an earlier stage of CKD [27–29]. As a practical point, the
way to demonstrate the accuracy of a particular method
for estimating GFR may be to evaluate its ability to predict
adverse clinical outcomes [27, 32]. In other words, improve-
ment in the ability of an eGFR equation to predict adverse
outcomes may reflect more accurate estimation of GFR by
said equation. In this regard, the CKD-EPI equation might
be the most accurate method for estimating GFR in various
populations [1, 18, 30]. Despite increasing evidence of the
merits of the CKD-EPI equation, only one study to date
has been performed comparing the MDRD study equation
with the CKD-EPI equation for predicting adverse clinical
outcomes in type 2 diabetic patients, in which the CKD-
EPI equation reportedly predicted mortality more accurately
than the MDRD study equation did [31]. However, in the
present study, we failed to observe a significant difference in
predicting all-cause mortality, ESRD, AMI, or stroke (data
not shown). This might be due to the relatively small sample
size and short follow-up times (median follow-up: 2.4 years).
Overall, our results suggest that improved estimation of GFR
by the CKD-EPI equation, compared to the MDRD study
equation, allowed for better risk categorization for decline in
renal function in T2D patients in Korea.
In addition to the retrospective nature of our study, there
are a few important limitations that warrant consideration.
First, we did not evaluate the accuracy of the two eGFR
equations for estimating GFR in type 2 diabetic patients
with nephropathy in comparisonwith directlymeasuredGFR
(e.g., GFR measurement by using inulin or isotope). Sec-
ond, although the CKD-EPI equation holds greater clinical
implications than theMDRD study equation in patients of an
earlier stage of CKD, it still involves the inherent limitations
of serum creatinine, which is dependent on muscle mass,
generation, and tubular secretion [11].Thirdly, we followed up
the subjects for a relatively short term (median, 2.4 years) and
had no information about potential confounding factors (e.g.,
smoking). Therefore, some important clinical outcomes such
as ESRD or mortality could not be appropriately evaluated.
Lastly, this study comprised only Korean patients with T2D,
preventing our results from being generalized to other ethnic
populations.
Regarding management of subjects with T2D, long-term
medical complications such as CVD and ESRD should
be taken into account, especially in those with diabetic
nephropathy who are more prone to deteriorations in renal
function and are at higher risk for comorbidities, such as
CVD and mortality. In this regard, accurate prediction for
possible progression to renal failure might be one of the most
important clinical endpoints in evaluating diabetic patients
who show the potential for unwanted clinical outcomes.
In accordance with previous reports and our results, the
CKD-EPI equation could be considered an optimal equa-
tion in evaluating persons with normal renal function or
earlier stage of CKD, a clinical scenario similar to early
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Table 2: Crude and adjusted Cox proportional hazard ratios for doubling of baseline serum creatinine level in 707 type 2 diabetic patients
with nephropathy stratified by CKD stage according to each equation.
HR 95% CI 𝑃 HR 95% CI 𝑃
CKDMDRD <0.0001 CKDCKD-EPI <0.0001
Stage 1: ≥90 1 Reference Stage 1: ≥90 1 Reference
Stage 2: 60–89 1.54 0.72–3.32 0.2679 Stage 2: 60–89 1.90 0.97–3.73 0.0630
Stage 3a: 45–59 1.79 0.79–4.07 0.1658 Stage 3a: 45–59 2.18 1.04–4.55 0.0383
Stage 3b: 30–44 4.11 1.92–8.82 0.0003 Stage 3b: 30–44 4.31 2.19–8.48 <0.0001
Stage 4: 15–29 4.40 2.04–9.49 0.0002 Stage 4: 15–29 5.08 2.56–10.08 <0.0001
Stage 5: <15 6.64 2.66–16.61 <0.0001 Stage 5: <15 8.09 3.65–17.95 <0.0001
Adjusted model 1 <0.0001 Adjusted model 1 <0.0001
Stage 1: ≥90 1 Reference Stage 1: ≥90 1 Reference
Stage 2: 60–89 1.13 0.57–2.21 0.7311 Stage 2: 60–89 1.56 0.84–2.89 0.1564
Stage 3a: 45–59 1.73 0.85–3.51 0.1324 Stage 3a: 45–59 2.42 1.26–4.67 0.0083
Stage 3b: 30–44 3.63 1.83–7.18 0.0002 Stage 3b: 30–44 4.29 2.29–8.02 <0.0001
Stage 4: 15–29 4.20 2.10–8.37 <0.0001 Stage 4: 15–29 5.47 2.89–10.35 <0.0001
Stage 5: <15 5.83 2.62–12.98 <0.0001 Stage 5: <15 8.17 3.98–16.78 <0.0001
Adjusted model 2 <0.0001 Adjusted model 2 <0.0001
Stage 1: ≥90 1 Reference Stage 1: ≥90 1 Reference
Stage 2: 60–89 1.12 0.55–2.28 0.7493 Stage 2: 60–89 1.70 0.88–3.28 0.1139
Stage 3a: 45–59 1.63 0.77–3.43 0.2013 Stage 3a: 45–59 2.32 1.14–4.70 0.0199
Stage 3b: 30–44 3.40 1.64–7.07 0.0010 Stage 3b: 30–44 4.39 2.22–8.67 <0.0001
Stage 4: 15–29 3.60 1.73–7.51 0.0006 Stage 4: 15–29 5.08 2.55–10.13 <0.0001
Stage 5: <15 5.34 2.27–12.55 0.0001 Stage 5: <15 7.79 3.57–17.02 <0.0001
Adjusted model 3 <0.0001 Adjusted model 3 <0.0001
Stage 1: ≥90 1 Reference Stage 1: ≥90 1 Reference
Stage 2: 60–89 1.09 0.54–2.23 0.8093 Stage 2: 60–89 1.67 0.86–3.23 0.1270
Stage 3a: 45–59 1.49 0.70–3.18 0.2978 Stage 3a: 45–59 2.14 1.04–4.39 0.0379
Stage 3b: 30–44 3.42 1.64–7.12 0.0010 Stage 3b: 30–44 4.43 2.24–8.76 <0.0001
Stage 4: 15–29 3.60 1.72–7.53 0.0007 Stage 4: 15–29 5.14 2.57–10.28 <0.0001
Stage 5: <15 5.39 2.26–12.88 0.0001 Stage 5: <15 8.00 3.62–17.68 <0.0001
Adjusted model 4 <0.0001 Adjusted model 4 <0.0001
Stage 1: ≥90 1 Reference Stage 1: ≥90 1 Reference
Stage 2: 60–89 1.25 0.56–2.81 0.5848 Stage 2: 60–89 1.90 0.91–3.97 0.0874
Stage 3a: 45–59 1.44 0.60–3.46 0.4159 Stage 3a: 45–59 2.12 0.94–4.75 0.0688
Stage 3b: 30–44 3.22 1.40–7.43 0.0060 Stage 3b: 30–44 4.03 1.88–8.63 0.0003
Stage 4: 15–29 3.22 1.43–7.71 0.0051 Stage 4: 15–29 4.77 2.19–10.37 0.0001
Stage 5: <15 6.71 2.51–17.91 0.0001 Stage 5: <15 9.82 4.05–23.80 <0.0001
CKD: chronic kidney disease; HR: hazard ratio; CI: confidence interval; MDRD: modification of diet in renal disease; CKD-EPI: chronic kidney disease
epidemiology collaboration.
Model 1: adjusted for age and sex.
Model 2: adjusted for age, sex, and duration of diabetes.
Model 3: adjusted for age, sex, duration of diabetes, and baseline HbA1c level.
Model 4: adjusted for age, sex, duration of diabetes, baseline HbA1c level, and medication for hypertension.
stage diabetic nephropathy [18, 27–29]. Taken together, our
findings, despite their limitations, may hold several clinical
implications that warrant further investigation.
5. Conclusions
In conclusion, we suggest that the CKD-EPI equation is
superior to the MDRD study equation in identifying type 2
diabetic subjects with nephropathy prone to decline in renal
function. However, further studies are needed to verify the
accuracy and precision of the CKD-EPI equation compared
to the MDRD study equation in estimating GFR in more
diverse populations such as elderly patients, different ethnic
groups, and patients with T2D [18, 33].
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